I am a member of the interdisciplinary team working on PROPERMED (Prostate cancer - Personalized medicine powered by MRI and AI), a research initiative supported by NTNU Health. Our project's primary objective is to advance the use of AI-based decision support tools in personalized medicine for prostate cancer, bringing them closer to clinical implementation. Despite the vast potential, only a minority of AI-based solutions have been integrated into clinical practice. PROPERMED aims to bridge this gap through a comprehensive approach that involves technical AI development, prospective clinical testing, and the assessment of its societal impact. In this project, my main responsibilities involve establishing a framework for radiogenomics. This framework will link features derived from MRI scans with molecular analyses conducted on a substantial cohort of prostate cancer patients already recruited at NTNU/St. Olavs Hospital. The focus will be on extracting and combining features related to heterogeneity and inflammation, with the ultimate goal of identifying radiogenomic signatures that can effectively differentiate high- and low-risk prostate cancer cases.